CN101336109A - 用于治疗和诊断下肢不宁综合征的方法与组合物 - Google Patents

用于治疗和诊断下肢不宁综合征的方法与组合物 Download PDF

Info

Publication number
CN101336109A
CN101336109A CNA2006800517948A CN200680051794A CN101336109A CN 101336109 A CN101336109 A CN 101336109A CN A2006800517948 A CNA2006800517948 A CN A2006800517948A CN 200680051794 A CN200680051794 A CN 200680051794A CN 101336109 A CN101336109 A CN 101336109A
Authority
CN
China
Prior art keywords
dopamine
iron
administration
ferrous
rls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800517948A
Other languages
English (en)
Chinese (zh)
Inventor
L·格罗特
J·赫德纳
K·斯滕洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cereuscience AB
Original Assignee
Cereuscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cereuscience AB filed Critical Cereuscience AB
Publication of CN101336109A publication Critical patent/CN101336109A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800517948A 2005-12-20 2006-12-06 用于治疗和诊断下肢不宁综合征的方法与组合物 Pending CN101336109A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE05028303 2005-12-20
SE0502830 2005-12-20

Publications (1)

Publication Number Publication Date
CN101336109A true CN101336109A (zh) 2008-12-31

Family

ID=38188943

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800517948A Pending CN101336109A (zh) 2005-12-20 2006-12-06 用于治疗和诊断下肢不宁综合征的方法与组合物

Country Status (11)

Country Link
US (1) US20090304816A1 (https=)
EP (1) EP1973551A1 (https=)
JP (1) JP2009520023A (https=)
KR (1) KR20080078075A (https=)
CN (1) CN101336109A (https=)
AU (1) AU2006327254A1 (https=)
CA (1) CA2634140A1 (https=)
EA (1) EA200801540A1 (https=)
IL (1) IL192325A0 (https=)
WO (1) WO2007073325A1 (https=)
ZA (1) ZA200805358B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
US10617694B2 (en) * 2016-05-11 2020-04-14 Jan Hedner Sultiame for the treatment of sleep apnea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US6960571B2 (en) * 2003-03-14 2005-11-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
EP1635804B1 (fr) * 2003-05-30 2016-09-21 NLS-1 Pharma AG Utilisation du fer pour le traitement du trouble du deficit de attention/hyper-activite chez les enfants
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa

Also Published As

Publication number Publication date
EA200801540A1 (ru) 2008-12-30
IL192325A0 (en) 2009-02-11
US20090304816A1 (en) 2009-12-10
AU2006327254A1 (en) 2007-06-28
CA2634140A1 (en) 2007-06-28
ZA200805358B (en) 2009-04-29
JP2009520023A (ja) 2009-05-21
KR20080078075A (ko) 2008-08-26
EP1973551A1 (en) 2008-10-01
WO2007073325A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
US20010053777A1 (en) Drug treatment for restless leg syndrome
EP2564872B1 (fr) Mazindol en tant que seul principe actif ou en combinaison avec du fer pour le traitement du déficit de l'attention/hyperactivité
JP2003507420A (ja) 作用物質の組成物、クロニジンを含む前記組成物
EP1154795B1 (en) Means for treating and diagnosing restless legs syndrome
TWI802623B (zh) 一種(6S)-N-[4-({(2S,5R)-5-[(R)-羥基(苯基)甲基]吡咯啶-2-基}甲基)苯基]-4-側氧-4,6,7,8-四氫吡咯并[1,2-a]嘧啶-6-甲醯胺用於夜間頻尿治療劑之醫藥製造之用途
CA2737393A1 (en) Compositions and methods for minimizing or reversing agonist-induced desensitization
ES2346290T3 (es) Administracion nasal de metoclopramida para el tratamiento de gastroparesia.
JPH0232023A (ja) パーキンソン症候群の治療用薬剤
BR112020018362A2 (pt) Composição de glp-1 para tratar obesidade e controle de peso
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
EP1534289B2 (en) Adenosine a2a receptor antagonists for treating restless legs syndrome or nocturnal myoclonus
WO1998024411A2 (en) Method for oral administration of buspirone
BR112019010077A2 (pt) terapias para o tratamento de condições hipocalêmicas e de ineficácia da lidocaína
CN101336109A (zh) 用于治疗和诊断下肢不宁综合征的方法与组合物
ES2312657T3 (es) Utilizacion de desoxipeganina en el tratamiento de la depresion clinica.
WO2008010768A1 (en) Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method
JPH0539219A (ja) 胸やけ、胃痛または胃酸過多に関連した胃の不調の発泡性ｈ２ブロツカー製剤による治療
JPH10506097A (ja) Ｊｅｔ ｌａｇを緩和するための方法と医薬
AU2006272874B2 (en) Rapid onset and short term modafinil compositions and methods of use thereof
EP2724722B1 (en) Method of restoring the incretin effect
EP1611901B1 (en) Preventive or remedy for teeth grinding
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
CN1057207C (zh) 治疗人类骨质疏松症的协同药物结合物
HK40014066A (en) Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions
Perkins et al. Pharmacotherapy Options in Restless Legs Syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20081231